€4.20
-0.04 (-1.04%)
EUR · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ADOC.PA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
27 interventional
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Trial Investigating the Dose Linearity and Safety of BC Combo THDB0207 in Subjects With Type 2 DiabetesNCT05373212AUCTOTAL0-lastRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: Euglycemic clamp with BC Combo THDB0207, Euglycemic clamp with Humalog® Mix25 | Type 2 Diabetes | 40 | 2023-01-02actual | 2023-09-15 |
| A Trial Investigating the Pharmacodynamics of BC Combo THDB0207 Compared With Humalog® Mix25 and Simultaneous Injections of Humalog® and Lantus® in Healthy Chinese VolunteersNCT05373186AUCGIR 0-2hRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: Euglycemic clamp with BC Combo THDB0207, Euglycemic clamp with Humalog® Mix25, Euglycemic clamp with Humalog® and Lantus® | Healthy | 27 | 2022-12-04actual | 2023-10-12 |
| A Trial Comparing the Pharmacodynamics and Pharmacokinetics of BC Combo THDB0207 and Lantus® and Humalog® in Subjects With Type 1 DiabetesNCT05373199AUCGIR 0-6hRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: Euglycemic clamp with BC Combo THDB0207, Euglycemic clamp with Lantus®, Euglycemic clamp with Humalog® | Type 1 Diabetes | 30 | 2022-10-28actual | 2023-09-15 |
| A Trial to Assess the Efficacy and Safety of M1 Pram P037 Prandial Insulin in Subjects With Type 1 Diabetes (T1DM)NCT04816890Body weight change from baseline to week 16 of treatmentRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: M1 Pram P037, Insulin lispro | Type 1 Diabetes Mellitus | 80 | 2022-02-24actual | 2022-06-24 |
| A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes MellitusNCT04501107AUCGIR.0-12hRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Administration of BioChaperone insulin lispro reconstituted with Humalog® (IMP1), Administration of Ready-to-use BioChaperone insulin lispro (IMP2), Administration of US-approved Humalog® (IMP3), Administration of EU-approved Humalog® (IMP4) | Type 1 Diabetes | 32 | 2020-11-03actual | 2020-11-30 |
| A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes MellitusNCT03981627ΔAUCPG(0-4h)Randomized · Triple-masked · Treatment | Phase 1/2 | Completed | Drug: ADO09 formulation, NovoRapid® | Type 1 Diabetes Mellitus | 44 | 2020-06-27actual | 2020-11-30 |
| A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes MellitusNCT03916640CmaxPramRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: ADO09 formulation, Placebo, Symlin®, Humulin®, Humalog® | Type 1 Diabetes Mellitus | 24 | 2019-03-01actual | 2019-04-16 |
| A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes MellitusNCT03512236CmaxPramRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: BC Pram Ins, Symlin® and Humulin®, Humalog®, Placebo | Type 1 Diabetes Mellitus | 24 | 2019-02-14actual | 2019-02-21 |
| A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® Delivered by an Insulin PumpNCT03179332AUCGIR(0-60min)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: BioChaperone® insulin lispro, Fiasp®, Novorapid® | Type1 Diabetes Mellitus | 43 | 2017-09-27actual | 2017-12-12 |
| A Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With T1DMNCT03176524Clinical safety laboratoryRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: BioChaperone® glucagon formulation 1, BioChaperone® glucagon formulation 2, GlucaGen® HypoKit® | Type 1 Diabetes Mellitus | 27 | 2017-09-04actual | 2017-12-12 |
| A Trial to Investigate the Dose-linearity of BioChaperone® Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 DiabetesNCT03180710AUC last_totalRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: BioChaperone® Combo 75/25 at 0.6 U/kg, BioChaperone® Combo 75/25 at 0.8 U/kg, BioChaperone® Combo 75/25 at 1.0 U/kg, Humalog® Mix25 at 0.8 U/kg | Type 2 Diabetes Mellitus | 32 | 2017-08-28actual | 2018-01-10 |
| A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 DiabetesNCT02915250Delta AUC BG 0-2h (area under the blood glucose concentration-time curve)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: BioChaperone® Combo, Humalog® Mix25, Humalog®, Lantus®, Placebo | Type 2 Diabetes Mellitus | 36 | Jun 2017actual | 2017-06-29 |
| A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®NCT02562313Pharmacodynamics: ΔAUCBG 0-2hRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: BioChaperone insulin lispro, Humalog® | Type 1 Diabetes Mellitus | 80 | Nov 2016actual | 2016-11-22 |
| A Phase 3 Clinical Trial to Assess the Effectiveness of BioChaperone PDGF-BB In the Treatment of Chronic Diabetic Foot UlcerNCT02236793Incidence of complete wound closure.Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: BioChaperone PDGF-BB · Other: Standard of Care | Diabetic Foot Ulcer | 252 | Aug 2016actual | 2017-06-29 |
| A Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBet® Compared to Insulin Lispro (Humalog®) and Regular Human Insulin (Huminsulin® Normal) After Ingestion of a Standardized Meal in Subjects With T1DMNCT02739906BG1hRandomized · Triple-masked · Treatment | Phase 1/2 | Completed | Drug: BioChaperone Human Insulin (HinsBet®), Insulin Lispro (Humalog®), Regular human insulin (Huminsulin® Normal) | Type 1 Diabetes Mellitus | 36 | Aug 2016actual | 2016-08-18 |
| An Euglycemic Clamp Trial to Evaluate Pharmacokinetics of Single Doses of BioChaperone Insulin Lispro in Healthy Japanese SubjectsNCT02660502AUCLispro(0-30min)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Biochaperone insulin lispro 0.1 U/kg, Biochaperone insulin lispro 0.2 U/kg, Biochaperone insulin lispro 0.4 U/kg, Humalog® | Healthy | 15 | May 2016actual | 2016-05-30 |
| A Trial to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 2 Diabetes MellitusNCT02562326Pharmacodynamics: ΔAUCBG 0-2hRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: BioChaperone insulin lispro, Humalog® | Type 2 Diabetes Mellitus | 51 | Jan 2016actual | 2016-04-29 |
| To Investigate the Efficacy and Safety of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 1 Diabetes MellitusNCT02528396AUCΔBG0-2h (timepoint 0 = administration of the meal)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: BioChaperone insulin lispro, Humalog® | Type 1 Diabetes Mellitus | 36 | Dec 2015actual | 2016-03-16 |
| A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 DiabetesNCT02514850Area under the glucose infusion rate curve (AUCGIR) 12-30h (mg/kg)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: Biochaperone Combo, Humalog Mix25, Humalog, Lantus, Placebo | Type 2 Diabetes Mellitus | 24 | Nov 2015actual | 2015-12-02 |
| Postprandial Blood Glucose Control With BioChaperone® Combo and Insulin Lispro (Humalog®) Mix 25 in People With Type 1 Diabetes MellitusNCT02514954Delta AUCBG,0-2hRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: Biochaperone® Combo, Humalog® Mix25 | Type 1 Diabetes Mellitus | 28 | Nov 2015actual | 2015-11-06 |
| A Clinical Trial Investigating the Intra-subject Variability of Pharmacokinetics and Glucodynamics of BioChaperone Insulin Lispro U-100 Product and U-200 Product in Healthy VolunteersNCT02529293AUCLisp (0-inf)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: BioChaperone Lispro U-100, BioChaperone Lispro U-200 | Healthy | 26 | Nov 2015actual | 2015-12-18 |
| Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized MealNCT02344992Area under the blood glucose time curve: AUCbg(0-2h)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: BioChaperone insulin lispro, Humalog® | Diabetes Mellitus Type 1 | 38 | Jun 2015actual | 2017-06-01 |
| A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 DiabetesNCT02213146Area under the curve (AUCins(0-1h))Randomized · Quadruple-masked · Treatment | Phase 1/2 | Completed | Drug: BioChaperone human insulin, Huminsulin® Normal, Humalog® | Diabetes Mellitus Type 1 | 38 | Dec 2014actual | 2017-06-01 |
| A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 DiabetesNCT02146651Glucodynamic endpoint: Area Under the Curve GIR(0-last)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: BioChaperone insulin lispro 0.2U/Kg, BioChaperone insulin lispro 0.1U/Kg, BioChaperone insulin lispro 0.4U/Kg, Humalog® | Diabetes Mellitus Type 1 | 38 | Jul 2014actual | 2014-12-10 |
| A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 DiabetesNCT02029924Area under the curve (AUC)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: BioChaperone insulin lispro, Humalog® | Diabetes Mellitus Type 1 | 37 | Mar 2014actual | 2017-06-01 |
| A Trial to Assess the Efficacy and Safety of BioChaperone Combo and Humalog Mix 25 in Subjects With Type 1 DiabetesNCT01981031End of action of 0.8 U/kg BioChaperone® Combo (time from administration until blood glucose concentration is consistently above 8.3 mmol/L during the glucose clamp procedure)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: BioChaperone® Combo, Humalog® Mix25 | Diabetes, Diabetes Mellitus, Type 1 | 21 | Dec 2013actual | 2017-06-01 |
| A Study of Insulin Lispro With BioChaperone Excipient in Healthy ParticipantsNCT01638325Pharmacokinetics: Area under the concentration curve (AUC)Randomized · Single-masked · Basic science | Phase 1 | Completed | Drug: Insulin Lispro, BC106 insulin lispro | Healthy Participants | 37 | Sep 2012actual | 2014-06-16 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19